HyStem® hydrogels were developed out of Glycosan BioSystems in 2006. The Glycosan technology is based on cross-linking modified hyaluronan, a naturally-occurring component of the extracellular matrix of connective, epithelial, and neural tissues, with modified gelatin derived from natural collagen. The combination of modified macro-molecules in the presence of a cross-linker, results in a biocompatible, resorbable hydrogel. The Glycosan technology under the HyStem® hydrogel brand is highly customizable and biocompatible, making it ideal for research use. The timing of gel formation upon mixing components is extremely flexible and can easily be controlled so that cellular proteins, chemically-defined material, or cells can be incorporated into the forming hydrogel to test a wide range of experimental parameters. Gel viscosity and stiffness is controlled through cross-linking of the hydrogel without the formation of undesirable bi-products or temperature or pH changes that may otherwise compromise experimental samples.
Biotime, Inc. holds exclusive worldwide rights to a patent estate that was licensed from the University of Utah Research Foundation with broad claims to product chemical composition, method of crosslinking, method of preparation, and the use of the synthetic extracellular matrix.
ESI BIO’s human embryonic stem cell (hESC) lines have been derived under conditions that adhere to global ethical standards and conform to regulations controlling clinical-grade cell and tissue development (current Good Tissue Practices) and comply with current Good Manufacturing Practices (cGTPs and cGMPs). ESI BIO's hES cell lines are among the best-characterized and documented lines available today.
These cell lines have been approved by the National Institutes of Health (NIH) and are included in the NIH Stem Cell Registry.
ESI BIO provides clonally pure cultures of human embryonic progenitor cells (hEPC). NIH-registered human embryonic stem cells were cultured under an array of differentiation conditions and time periods, creating hundreds of colonies containing thousands of types of unique transient embryonic progenitor cells. These hEPC are normally transient, existing for a short time in an embryo before they receive a signal to change into the next cell type in its developmental pathway.
These transient progenitors show characteristics not observed in adult stem cells, including differentiation to tissues that may be more appropriate for therapy such as chondrogenic cells that do not express markers of hypertrophic cartilage. They are highly proliferative, producing scalable cultures free of hazardous totipotent cells.
所有产品分类